U.S. markets close in 5 hours 36 minutes
  • S&P 500

    3,453.59
    +26.67 (+0.78%)
     
  • Dow 30

    28,395.15
    +199.73 (+0.71%)
     
  • Nasdaq

    11,564.37
    +85.48 (+0.74%)
     
  • Russell 2000

    1,629.50
    +15.87 (+0.98%)
     
  • Crude Oil

    40.68
    -0.15 (-0.37%)
     
  • Gold

    1,905.20
    -6.50 (-0.34%)
     
  • Silver

    24.78
    +0.08 (+0.33%)
     
  • EUR/USD

    1.1840
    +0.0067 (+0.57%)
     
  • 10-Yr Bond

    0.7960
    +0.0350 (+4.60%)
     
  • GBP/USD

    1.2971
    +0.0030 (+0.23%)
     
  • USD/JPY

    105.5700
    +0.1400 (+0.13%)
     
  • BTC-USD

    11,925.15
    +868.14 (+7.85%)
     
  • CMC Crypto 200

    240.09
    +1.17 (+0.49%)
     
  • FTSE 100

    5,908.43
    +23.78 (+0.40%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

Monthly information on share capital and company voting rights

Cellectis Inc.
·2 mins read

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting rights

09/30/2020

42,486,133

47,940,528

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Jennifer Moore, SVP, Public Relations & NY Site Head 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

IR contact:
Simon Harnest, VP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

PDF available at: http://ml.globenewswire.com/Resource/Download/f3a3de01-67b4-4acd-b59a-32077058ee2f